This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
2 Apr 2011

BARDA Grants Biota $231 Flu Vaccine Contract

BARDA is giving $231 million to Australia-based Biota for the company's flu treatment laninamivir.

Just a month after granting major contracts to VaxInnate and Novavax, the Office of Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS) is giving $231 million to Australia-based Biota for the company's flu treatment laninamivir. The drug is already approved in Japan but is several years away from approval in the U.S.

 

Related News